# Cleancard **Source:** https://geo.sig.ai/brands/cleancard **Vertical:** Healthcare **Subcategory:** General **Tier:** Emerging **Website:** cleancard.bio **Last Updated:** 2026-04-14 ## Summary US YC S23 at-home 30-minute cancer screening for prostate, bladder, and ovarian cancers; $846K Mayo Clinic/TQ Ventures/YC-backed with synthetic biology + computer vision from Oxford Rhodes Scholar founders competing with GRAIL for accessible early cancer detection. ## Company Overview Cleancard is a United States-based at-home cancer screening company — backed by Y Combinator (S23) with $846,000 in total funding from Mayo Clinic Platform, TQ Ventures, Urban Innovation Fund, Y Combinator, and the Creative Destruction Lab — developing a 30-minute at-home diagnostic platform that combines synthetic biology, machine learning, and computer vision to detect multiple cancer biomarkers from a single patient sample for prostate, bladder, and ovarian cancers. Founded by Luca Springer and Thomas Carroll (both Rhodes Scholars from Oxford), Cleancard targets the massive unmet need for accessible, affordable cancer screening outside of clinical settings — the 30-minute result time and home-based format enabling screening at the frequency and convenience required for early cancer detection programs. Cleancard's at-home cancer screening technology addresses the access and adherence barriers that reduce the effectiveness of existing cancer screening programs: prostate-specific antigen (PSA) testing, bladder cancer urine cytology, and ovarian cancer CA-125 testing are all clinic-based procedures that require scheduling appointments, traveling to labs, and waiting days for results — friction that causes eligible patients to skip routine screening or delay follow-up after abnormal results. Cleancard's platform uses synthetic biology-engineered biosensors (designed to detect specific cancer biomarker proteins or genetic signatures in urine or blood samples) combined with computer vision analysis of the test result pattern (reading the quantitative biomarker level from the test strip or cartridge format) to deliver clinical-grade sensitivity and specificity in a consumer-facing format. The multiplexable format (detecting multiple cancer biomarkers from a single sample) enables panel testing that improves early detection probability compared to single-marker testing — a key advance over current single-analyte home tests. Mayo Clinic Platform's investment provides the clinical validation infrastructure and healthcare system distribution relationships that consumer diagnostic companies require for clinical adoption. In 2025, Cleancard competes in the at-home diagnostics, cancer screening, and consumer health testing market with Galleri (Illumina/GRAIL multi-cancer early detection liquid biopsy, $1.9B raised), Exact Sciences (NASDAQ: EXAS, Cologuard colorectal cancer screening, $1B revenue), and EarlySign (AI-based early cancer detection, $21M raised) for consumer and healthcare system early cancer detection platform adoption. Mayo Clinic Platform's partnership (Mayo Clinic is one of the world's most trusted healthcare institutions) provides clinical validation credibility critical for consumer cancer diagnostic adoption where clinical trust is paramount. Rhodes Scholar founding team backgrounds reflect the academic research rigor that translates synthetic biology biosensor research into manufacturable consumer diagnostic products. The 2025 strategy focuses on achieving clinical validation data for the prostate and bladder cancer panels, pursuing FDA 510(k) clearance for at-home use authorization, and building the telehealth follow-up pathway for patients with positive screening results. ## Frequently Asked Questions ### What is Cleancard? Cleancard is a healthcare tech company that develops at-home cancer screening platforms using synthetic biology, machine learning, and computer vision. The company provides 30-minute diagnostic tests for prostate, bladder, and ovarian cancers with a focus on early detection and accessibility. ### What products and services does Cleancard offer? Cleancard offers at-home cancer screening tests that deliver results in 30 minutes for prostate, bladder, and ovarian cancers. Their tests use a multiplexable machine-readable format that can detect multiple cancer biomarkers from a single sample. ### Who is Cleancard's target customer? Cleancard targets cancer screening healthcare providers. Their platform is designed to make early cancer detection more accessible to patients through at-home testing. ### When was Cleancard founded? Cleancard was founded in 2023. The company participated in Y Combinator's Summer 2023 batch. ### Where is Cleancard located? Cleancard is based in San Francisco, California, United States. ### How much funding has Cleancard raised? Cleancard has raised $846,000 in funding from Mayo Clinic Platform, TQ Ventures, Urban Innovation Fund, Y Combinator, and Creative Destruction Lab. ### Who founded Cleancard? Cleancard was founded by Luca Springer and Thomas Carroll, who are both Rhodes Scholars from Oxford. ### What technology does Cleancard use? Cleancard combines synthetic biology, machine learning, and computer vision to develop their diagnostic tests. Their platform uses a multiplexable machine-readable format to detect multiple cancer biomarkers from a single sample. ### How long does a Cleancard test take? Cleancard's at-home cancer screening tests deliver results in 30 minutes. ### What types of cancer can Cleancard detect? Cleancard's platform can screen for prostate cancer, bladder cancer, and ovarian cancer. Their technology enables detection of multiple cancer biomarkers from a single sample. ## Tags healthtech, b2b, north-america --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*